INSP Inspire Medical Systems, Inc.

CIK 0001609550 23 ready 8-Ks latest May 5, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 23

Latest filing May 5, 2026, 7:59 PM ET

Top materiality 0.85

Event mix earnings ×12 · other_material ×8 · leadership ×2

Sentiment 12 pos · 3 neg · 8 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for INSP

Highest-materiality recent filing

Inspire Q4 rev $269M (+12%), EPS $4.66; FY26 outlook lowered on coding change

February 11, 2026, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 5.03 item 7.01 item 9.01 ◈ Governance Changes ×2

Q4 revenue $269.1M (+12%); GAAP diluted EPS $4.66; adjusted EPS $1.65.
Full year revenue $912M (+14%); operating cash flow $117M; share repurchases $175M.

Read filing →

May 5, 2026, 7:59 PM ET other material materiality 0.55 neutral item 5.02 item 5.07 item 5.03 item 9.01 ◈ Governance Changes

Inspire Medical shareholders approve declassification, 2.6M-share increase to equity plan

Stockholders approved phasing out classified board; all directors to be elected annually starting 2029.
May 4, 2026, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

Inspire Medical Q1 revenue up 1.6% to $204.6M; guides FY2026 revenue down 4-10%

GAAP diluted EPS $(0.39); adjusted diluted EPS $0.10; operating cash flow $12.8M.
February 11, 2026, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 5.03 item 7.01 item 9.01 ◈ Governance Changes ×2

Inspire Q4 rev $269M (+12%), EPS $4.66; FY26 outlook lowered on coding change

Q4 revenue $269.1M (+12%); GAAP diluted EPS $4.66; adjusted EPS $1.65.
January 12, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 5.02 item 7.01 item 9.01

Inspire Medical posts preliminary Q4 rev ~$269M (+12% YoY); 2026 guidance $1,003-1,013M

Preliminary Q4 2025 revenue ~$269M, up 12% YoY; full-year 2025 revenue ~$912M, up 14% YoY.
November 17, 2025, 6:59 PM ET other material materiality 0.85 positive item 8.01

Inspire Medical Systems expects $90M-$100M tax benefit from valuation allowance release

Company disclosed expectation to release a significant portion of valuation allowance on U.S. deferred tax assets.
November 3, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

Inspire Medical Q3 revenue $224.5M (+10% YoY); net income down; FY25 EPS guidance raised to $0.90-$1.00

Revenue $224.5M in Q3 2025, up 10% from $203.2M a year ago; U.S. revenue $214.4M (+9%), OUS revenue $10.1M (+37%).
October 10, 2025, 7:59 PM ET other material materiality 0.80 positive item 7.01 item 9.01

Inspire V clinical data shows superior efficacy, adherence, and reduced surgical times; AHI cut from 34.4 to 8.3

Singapore study (44 patients): Inspire V IPOP 87.1% vs Inspire IV 79.4%, exceeding non-inferiority margin of 4.6%.
August 26, 2025, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01

Inspire Medical Systems CFO Rick Buchholz to step down by Dec 31, 2025; 2025 guidance reaffirmed

CFO Rick Buchholz resigns effective Dec 31, 2025, will remain in advisory role through Feb 28, 2026.
August 11, 2025, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Inspire Medical Systems board authorizes $200M share repurchase program

Board authorized repurchase of up to $200M of common stock.
August 4, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 5.02 item 7.01 item 9.01

Inspire Medical Q2 net loss $3.6M, cuts FY 2025 revenue guidance to $900-910M

Q2 revenue $217.1M (+11% YoY), net loss $3.6M vs prior year net income $9.8M.
June 13, 2025, 7:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

Inspire Medical Systems files investor presentation for June 2025 meetings

Company will participate in investor and analyst meetings in June 2025.
May 5, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Inspire Medical Q1 rev $201.3M (+23% YoY), EPS $0.10; raises FY EPS guidance to $2.20-$2.30

Revenue $201.3M, up 23% YoY; U.S. revenue $193.6M (+24%), OUS $7.7M (-6%).
May 5, 2025, 7:59 PM ET other material materiality 0.10 neutral item 5.07

Inspire Medical stockholders approve all proposals at 2025 annual meeting

All three Class I director nominees elected: Burks (20.5M for), Herbert (21.1M for), McCormick (19.9M for).
February 10, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Inspire Medical Q4 revenue $239.7M (+25% YoY); EPS $1.15; guides FY2025 rev $940-955M

Q4 revenue $239.7M (+25% YoY); net income $35.2M, diluted EPS $1.15 vs $0.49 prior year.
January 13, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Inspire Medical reports Q4 revenue ~$239.7M (+25% YoY); issues 2025 guidance $940-955M

Preliminary Q4 2024 revenue ~$239.5-239.7M, up 25% YoY; full year 2024 revenue ~$802.6-802.8M, up 28% YoY.
November 12, 2024, 6:59 PM ET other material materiality 0.55 neutral item 8.01

Inspire Medical enters $75M accelerated share repurchase with Goldman Sachs

ASR agreement for $75M repurchase under existing $150M buyback program authorized by Board.
November 4, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Inspire Medical Q3 revenue $203.2M (+33% YoY), EPS $0.60 vs loss, raises FY guidance

Revenue $203.2M, up 33% YoY; U.S. revenue $195.8M (+33%), OUS $7.4M (+27%).
August 6, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 8.01 item 9.01

Inspire Q2 revenue $195.9M (+30% YoY), EPS $0.32; raises FY guide, authorizes $150M buyback

Q2 revenue $195.9M (30% YoY), net income $9.8M vs loss $12.0M; diluted EPS $0.32 vs ($0.41).
August 2, 2024, 7:59 PM ET regulatory materiality 0.80 positive item 8.01 item 9.01

Inspire Medical receives FDA approval for next-gen Inspire V neurostimulation system

FDA approved Inspire V system including next-generation neurostimulator, Bluetooth patient remote, and physician programmer.
July 29, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Inspire Medical pre-announces Q2 revenue $195.9M (+30% YoY), raises 2024 guidance to $788-798M

Q2 revenue $195.9M, up 30% YoY; US revenue $187.8M (+30%), OUS $8.1M (+27%).
July 22, 2024, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change

Inspire Medical COO Philip Ebeling resigns effective Aug 9 to become CEO at private cardiology device firm

Philip J. Ebeling notified Inspire Medical on July 18, 2024 of his resignation as COO, effective Aug 9, 2024.
May 7, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

Inspire Medical Q1 revenue $164M (+28% YoY); raises FY2024 guidance, expects full-year profitability

Q1 2024 revenue $164.0M, up 28% YoY; net loss narrowed to $10.0M ($0.34/share) from $15.4M.
May 7, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

Inspire Medical shareholders elect directors, ratify auditor, approve say-on-pay

All three Class III director nominees elected: Broader (26.3M for), Dr. Curet (23.5M for), Tansey (26.1M for).

Executive changes

Departed

Philip J. Ebeling

Chief Operating Officer

INSP · Inspire Medical Systems, Inc.

Effective: 2024-08-09
Filed: July 22, 2024, 7:59 PM ET

On July 18, 2024, Philip J. Ebeling notified Inspire Medical Systems, Inc. (the “ Company ”) of his decision to resign as Chief Operating Officer of the Company, effective as of August 9, 2024, in order to pursue a new professional opportunity as President and Chief Executive Officer of a private medical device company operating in the cardiology space.

Earnings & guidance

2026-Q1 EPS reported -$0.39 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.80 · Most common event earnings

12 positive 3 negative 8 neutral

source · INSP on sec.gov